Search results

• Leveraging Group-wide capabilities to accelerate the development of natural active ingredients

  The move in cosmetics towards replacing synthetic ingredients with sustainable alternatives is increasing demand for naturally sourced actives.

• Bio based Industry Story of the Year Winner

  Croda have been awarded the 2019 Bio-Based World News Innovation Award for “Bio-based Industry Story of the Year”

• Transition to bio-based MPG

  Transitioning our raw materials to bio-based sources will enable us to make a significant positive impact.

• Commitment to Science Based Targets

  We are proud to be one of around 600 companies taking science-based climate action, by committing to Science Based Targets

• 1.5°C science-based target validation

  In July 2021 we became only the third major chemical company globally to have a 1.5ºC science-based target validated.

• Acquisition of global vaccine adjuvant specialist

  Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

• Croda acquires research enterprise Enza Biotech

  Developing the next generation of renewable surfactants using carbohydrate-based chemistry.

• Acquisition of global vaccine adjuvant specialist

  Vaccine adjuvants are a natural extension to Croda’s market leading, high-purity excipient delivery systems in its Health Care business., these adjuvants represent a niche, high-growth market.

• Croda and Anome Collaboration Promises a Positive Difference in Beauty Effects

  We are very proud to announce a new collaborative partnership with Anomera, an award-winning innovator in green chemistry, materials science and sustainable manufacturing.

• Construction underway on our new North American Headquarters and innovation centre

  The sustainable facility will bring together commercial and technical teams from across our business areas

• Validation of our 1.5°C Science Based Targets

  We have become one of only three major chemical companies in the world to have our 1.5°C Science Based Targets validated.

• Investing in mRNA and gene therapy

  As the core of our lipid systems capability within the Health Care business, Avanti is primarily focused on developing innovative lipid-based products of unparalleled purity to address specific medical challenges that are not resolved by current technology.

• Supplying delivery systems to help prevent cardiovascular disease

  Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.

• Croda acquires marine biotechnology specialists Nautilus

  World class scientists, focusing on using marine microbial biodiversity to discover novel actives and materials for applications across all Croda market sectors.

• Croda expands Iberchems fragrances offering with the acquisition of Parfex

  Croda has acquired a controlling majority 95.6% of Parfex’s outstanding shares, comprising the founding shareholders and certain minority investors.

• Acquisition of Alban Muller

  The acquisition expands Croda’s portfolio of sustainable active ingredients for customers in personal care markets.

• Croda joins KTN SME accelerator programme

  Supporting UK-based SMEs and start-ups to bring their technology closer to market through the KTN accelerator programme

• Launch of Croda Pharma

  23 May 2022: Our Health Care division becomes Croda Pharma

• Sustainability success with EcoVadis rating

  24 May 2022: Sustainability success after retaining its position within the top 1% of companies assessed by EcoVadis

• Oil and Gas Portfolio Strengthened by Acquisition

  Global speciality chemical manufacturer Croda, announces the acquisition of JD Horizons Limited, a UK based business specialising in ‘Solutions for Flow Assurance’ technology.